Published on : 20 Jan, 2014
IMRE's spin-off company, ACM Biolabs, will market novel plastic cell membranes to be used as low-cost, easily maintained drug targets that help shorten the drug discovery process. The artificial cell membranes (ACMs) are customised synthetic cell membranes that mimic live, targeted membrane proteins and which can be tailor-made to a pharmaceutical company’s specific drug testing requirements, can be produced rapidly and are stable over a long period, leading to significantly reduced costs and streamlining of the currently tedious and cumbersome drug discovery process. The patented ACMs were developed at A*STAR’s IMRE in 2009 by integrating biology with innovative materials.
Download full media release here
Last update : 8/3/2015 2:11:30 PM